

# TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.  
Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com  
Corporate Identity Number : L24249MH1972PLC015544

Ref No: TPL PP 0625 2019

10<sup>th</sup> August, 2019

To

BSE Limited

Corporate Relationship Department,

1<sup>st</sup> Floor New Trading Ring,

Phiroze Jeejeebhoy Towers, Dalal Street, Fort,

Mumbai: 400 001.

Dear Sir / Madam,

Sub: Submission of Un-audited Financial Results for the Quarter ended 30<sup>th</sup> June, 2019

Ref: Security Code No. 512101 - ISIN No.: INE331E01013.

We refer to our letter dated 1<sup>st</sup> August, 2019 on the captioned subject.

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, In this regard, we wish to inform you that the Board of Director in its meeting held today i.e. Saturday, 10<sup>th</sup> August, 2019 has considered and approved the Un-audited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2019 duly reviewed by the Audit Committee. The said financial results, duly signed by the Director & CEO of the company and the auditor's report thereon are enclosed for your perusal and records.

The Audited financial results will be published in English and Marathi dailies newspaper on 11<sup>th</sup> August, 2019, as required. Please take the same in your records.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR & CEO

DIN: 00312369


Encl.: as above

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")**

1. We have reviewed the accompanying statement of unaudited financial results of **TRIOCHEM PRODUCTS LIMITED ("Company")** for the quarter ended June 30, 2019 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
2. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP  
Chartered Accountants  
Firm Registration No: 104746W/W100096



Kunal Vakharia  
Partner  
Membership No.: 148916  
UDIN:  
Place: Mumbai  
Date: 10<sup>th</sup> August, 2019



UDIN - 19148916AAAACK4161



# TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com

Corporate Identity Number : L24249MH1972PLC015544

## TRIOCHEM PRODUCTS LIMITED

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: [www.triochemproducts.com](http://www.triochemproducts.com)

CIN : L24249MH1972PLC015544

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019

(Rs in Lakhs) Except EPS					
Sr. No.	Particulars	Quarter Ended			Year Ended
		30-Jun-19 (Unaudited)	31-Mar-19 (Audited)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
1	<b>Income</b>				
	(a) Revenue from operations	52.60	339.97	670.72	1,235.47
	(b) Other income	0.16	1.53	1.02	5.52
	<b>Total Income From Operations</b>	52.76	341.50	671.74	1,240.99
2	<b>Expenses</b>				
	(a) Cost of materials consumed	-	458.38	609.25	1,099.78
	(b) Purchase of stock in trade	-	-	6.00	55.60
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	35.90	(260.24)	(92.47)	(311.83)
	(d) Employee benefit expenses	15.52	17.61	17.81	71.90
	(e) Finance costs	5.16	8.00	11.66	45.46
	(f) Depreciation and amortisation expense	4.16	5.11	5.11	20.54
	(g) Other expenses	30.93	46.84	38.56	155.59
	<b>Total expenses</b>	91.67	275.71	595.94	1,137.04
3	<b>Profit / (Loss) from ordinary activities before exceptional items (1-2)</b>	(38.91)	65.80	75.80	103.96
4	Exceptional items	-	-	-	-
5	<b>Profit / (Loss) before tax (3 +/- 4)</b>	(38.91)	65.80	75.80	103.96
6	<b>Tax Expense</b>				
	(a) Current tax	-	20.15	22.17	30.75
	(b) Deferred tax	(10.78)	3.32	(2.86)	(1.10)
	<b>Total tax expenses</b>	(10.78)	23.47	19.31	29.65
7	<b>Profit / (Loss) for the period (3 +/- 6)</b>	(28.13)	42.32	56.49	74.30
8	<b>Other comprehensive income, net of income tax</b>				
	(A)(i). Items that will be reclassified to profit or loss	-	-	-	-
	(ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	(B)(i). Item that will not be reclassified to profit or loss	0.01	(0.14)	(0.38)	0.02
	(ii). Income tax relating to items that will not be reclassified to profit or loss	(0.01)	0.03	0.10	(0.01)
	<b>Total other Comprehensive Income (net of taxes)</b>	-	(0.11)	(0.28)	0.01
9	<b>Total Comprehensive Income for the period</b>	(28.13)	42.21	56.21	74.31
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50
11	Other equity as per Balance Sheet of previous accounting year				853.07
12	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)				
	Basic / Diluted EPS (in Rs.)	(11.48)	17.27	23.06	30.33



ly

# TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com

Corporate Identity Number : L24249MH1972PLC015544

## Notes:

- 1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th August 2019. The Statutory auditors of the company has carried out a limited review of aforesaid results
- 2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant.
- 3) The figures of quarter ended 31st March 2019 are the balancing figures between audited figures of full financial year ended 31st March 2019 and published unaudited year to date figures upto third quarter 31st December 2018.
- 4) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 5) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai

Dated: 10th August, 2019

RAMU S. DEORA

DIRECTOR & CEO

DIN: 00312369





# TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Regd. Office : 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai - 400 001.

Tel. : 00 91 (22) 4082 8100 | Fax : 00 91 (22) 4082 8181 | E-mail : info@amphray.com

Corporate Identity Number : L24249MH1972PLC015544

## TRIOCHEM PRODUCTS LIMITED

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: [www.triochemproducts.com](http://www.triochemproducts.com)

CIN : L24249MH1972PLC015544

### EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019

(Rs in Lakh) Except EPS

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-Jun-19 (Unaudited)	31-Mar-19 (Unaudited)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
1	Net Operating Income	52.76	341.50	671.74	1,240.99
2	Profit / (Loss) for the period (before Interest, Depreciation, Taxes, Exceptional and / or Extraordinary items)	(29.59)	78.91	92.57	169.96
3	Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(38.91)	65.80	75.80	103.96
4	Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	(28.13)	42.32	56.49	74.30
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	-	(0.11)	(0.28)	0.01
6	Equity share capital (Face value of Rs.10/- per share)	24.50	24.50	24.50	24.50
7	Reserve (excluding Revaluation Reserves as shown in the Balance Sheet of previous year)				853.07
8	Earnings per equity share (EPS) (of Rs. 10/- each) (for continuing and discontinued operations)				
	a) Basic (not annualized)	(11.48)	17.27	23.06	30.33
	b) Diluted (not annualized)	(11.48)	17.27	23.06	30.33

#### Notes:

- 1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th August 2019. The Statutory auditors of the company has carried out a limited review of aforesaid results
- 2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant.
- 3) The figures of quarter ended 31st March 2019 are the balancing figures between audited figures of full financial year ended 31st March 2019 and published unaudited year to date figures upto third quarter 31st December 2018.
- 4) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 5) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- 6) The above is an extract of the detailed format of quarterly and half year ended financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the quarterly and half year ended financial results are available on the on the Stock Exchange and the Company namely [www.bseindia.com](http://www.bseindia.com) and [www.triochemproducts.com](http://www.triochemproducts.com)

FOR TRIOCHEM PRODUCTS LIMITED

**RAMU S. DEORA**  
DIRECTOR & CEO  
DIN: 00312369

Place: Mumbai

Dated: 10th August, 2019



Factory : Plot No. 10/2, MIDC Industrial Area, Chikholi, Ambernath (West), Dist. Thane, PIN - 421 505 MAHARASHTRA.

Tel. : 0251-268 2191 • 268 2711 | Fax : 0251-268 2192

General information about company	
Scrip code	512101
NSE Symbol	
MSEI Symbol	
ISIN*	INE331E01013
Name of company	Triochem Products Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2019
Date of end of financial year	31-03-2020
Date of board meeting when results were approved	10-08-2019
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	02-08-2019
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) Segment Reporting is not applicable.
Start date and time of board meeting	10-08-2019 16:00
End date and time of board meeting	10-08-2019 16:45
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

b

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	52.6	52.6
	Other income	0.16	0.16
	<b>Total income</b>	<b>52.76</b>	<b>52.76</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	35.9	35.9
(d)	Employee benefit expense	15.52	15.52
(e)	Finance costs	5.16	5.16
(f)	Depreciation, depletion and amortisation expense	4.16	4.16
(f)	<b>Other Expenses</b>		
1	Other expenses	30.93	30.93
10			
	<b>Total other expenses</b>	<b>30.93</b>	<b>30.93</b>
	<b>Total expenses</b>	<b>91.67</b>	<b>91.67</b>

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
3	<b>Total profit before exceptional items and tax</b>	-38.91	-38.91
4	Exceptional items	0	0
5	<b>Total profit before tax</b>	-38.91	-38.91
7	<b>Tax expense</b>		
8	Current tax	0	0
9	Deferred tax	-10.78	-10.78
10	<b>Total tax expenses</b>	-10.78	-10.78
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	<b>Net Profit Loss for the period from continuing operations</b>	-28.13	-28.13
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	<b>Total profit (loss) for period</b>	-28.13	-28.13



Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	0.01	0.01
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	-0.01	-0.01
5	Total Other comprehensive income	0	0

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
23	<b>Total Comprehensive Income for the period</b>	-28.13	-28.13
24	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	<b>Details of equity share capital</b>		
	Paid-up equity share capital	24.5	24.5
	Face value of equity share capital	10	10
27	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		
29	<b>Earnings per share</b>		
i	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	-11.48	-11.48
	Diluted earnings (loss) per share from continuing operations	-11.48	-11.48
ii	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	-11.48	-11.48
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	-11.48	-11.48
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

Text Block	
Textual Information(1)	<p>1) The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th August 2019. The Statutory auditors of the company has carried out a limited review of aforesaid results</p> <p>2) The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant.</p> <p>3) The figures of quarter ended 31st March 2019 are the balancing figures between audited figures of full financial year ended 31st March 2019 and published unaudited year to date figures upto third quarter 31st December 2018.</p> <p>4) The Company operates in single segment only, i.e. chemical and pharmaceuticals the disclosure requirement of Indian Accounting Standard (IND AS-108) " Segment Reporting" is not applicable.</p> <p>5) Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.</p>



<b>Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results</b>		
<b>Particulars</b>	<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
Date of start of reporting period	01-04-2019	01-04-2019
Date of end of reporting period	30-06-2019	30-06-2019
Whether accounts are audited or unaudited		
Nature of report standalone or consolidated	Standalone	Standalone
<b>1 Segment Revenue (Income)</b>		
<b>(net sale/income from each segment should be disclosed)</b>		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
<b>2 Segment Result</b>		
<b>Profit (+) / Loss (-) before tax and interest from each segment</b>		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
<b>3 (Segment Asset - Segment Liabilities)</b>		
<b>Segment Asset</b>		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
<b>4 Segment Liabilities</b>		
<b>Segment Liabilities</b>		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
<b>Disclosure of notes on segments</b>		

13